Clinical Trials on Circulating Tumor Cells in Czechia

Total 669 results

BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
GlaxoSmithKline

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

Neoplasms, Head and Neck

United States, Italy, Japan, Norway, Spain, Taiwan, Australia, United Kingdom, Belgium, Brazil, Germany, Greece, Romania, Sweden, Turkey, Canada, Korea, Republic of, China, France, Argentina, India, Poland, Israel, Portugal, Mexico, Czechia, Hunga...
AstraZeneca

Completed

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Squamous Cell Carcinoma of the Head and Neck

Croatia, Sweden, United States, Czech Republic, Italy, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Latvia, Lithuania, Norway, Canada, Netherlands, Argentina, Belgium, Greece, Thailand, India, Israel, Malaysia, ... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Non-small-cell Lung Carcinoma | Lung Carcinomas, Non-Small-Cell

Spain, Australia, Belarus, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Georgia, Greece, Hungary, Jordan, Lebanon, Malaysia, Mexico, Philippines, Poland, Romania, Russian Federation, Taiwan, Thailand, Turkey, Ukraine
Celgene

Completed

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (ROBUST)

Lymphoma, Large B-Cell, Diffuse

United States, Australia, Belgium, Canada, China, Czechia, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Switzerland, Taiwan, Turkey
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)

Gastrointestinal Stromal Tumors

United States, Australia, Germany, Spain, Korea, Republic of, Canada, France, Poland, Austria, Netherlands, Italy, Czech Republic, Switzerland
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Terminated

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, France, Poland, United Kingdom, Germany, Taiwan, Spain, Bulgaria, Romania, Turkey, Ukraine, Canada, Korea, Republic of, Netherlands, Russian Federation, Belgium, Brazil, Hungary, Czechia, Sweden
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor ((CITADEL-205))

Lymphoma

United States, Spain, France, United Kingdom, Czechia, Israel, Belgium, Italy, Germany, Poland, Denmark
Celgene

Completed

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Sprint)

Lymphoma, Mantle-Cell | Mantle Cell Lymphoma

France, United Kingdom, Belgium, Spain, Denmark, Germany, Israel, Russian Federation, Italy, Poland, Netherlands, Sweden, Greece, Czechia
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Spain, United States, Australia, France, Czechia, Hungary, Poland
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

Poland, United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Canada, Lithuania, Norway, Italy, Czechia, Estonia, Portugal
Shanghai Henlius Biotech

Recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer

United States, China, Greece, Spain, Austria, Czechia, Germany, Hungary, Latvia, Netherlands, Poland
BeiGene

Active, not recruiting

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

United States, China, Spain, Australia, Czechia, Japan, Belgium, Korea, Republic of, Italy, Germany, France, Romania, Poland, United Kingdom, Russian Federation, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
AbbVie (prior sponsor, Abbott)

Completed

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NSCLC | Lung Cancer | Non-Small-Cell Lung Cancer

United States, Czech Republic, Greece, Hungary, Netherlands, Slovakia
Bioven Europe

Terminated

Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (EGF)

Carcinoma, Non-Small-Cell Lung

Philippines, Spain, United Kingdom, Malaysia, Georgia, Thailand, Germany, Bulgaria, Czechia, Poland, Romania
GlaxoSmithKline

Completed

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma (ORCHARRD)

Lymphoma, Large-Cell, Diffuse

United States, Netherlands, Estonia, Spain, United Kingdom, Sweden, Israel, Poland, Belgium, Korea, Republic of, Singapore, Austria, Germany, Finland, Ireland, Thailand, China, Russian Federation, Czech Republic, Argentina, Denmark and more
MorphoSys AG

Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)

Diffuse Large B-cell Lymphoma

Germany, France, Hungary, Italy, Spain, United States, Austria, Czechia, Australia, Israel, Korea, Republic of, Turkey, Taiwan, Argentina, Canada, Colombia, Ireland, Japan, Malaysia, New Zealand, Philippines, Poland, Romania, Russian... and more
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Mantle-Cell Lymphoma

France, Canada, Spain, United States, Hungary, Korea, Republic of, Greece, Australia, Netherlands, Belgium, United Kingdom, Czechia, Germany, Poland, Italy, Turkey, Ukraine
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
Hoffmann-La Roche
Fondazione Italiana Linfomi ONLUS

Terminated

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Diffuse Large B-Cell Lymphoma

Italy, China, Korea, Republic of, Canada, Australia, United States, Austria, Brazil, Denmark, Panama, Peru, Spain, Colombia, United Kingdom, Switzerland, Thailand, Mexico, Taiwan, Hong Kong, Russian Federation, Hungary, Japan, Germany, South Africa and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
Blueprint Medicines Corporation

Completed

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST

United States, Korea, Republic of, Netherlands, China, France, Spain, Italy, Belgium, United Kingdom, Singapore, Australia, Canada, Germany, Sweden, Hungary, Austria, Czechia, Poland
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Lung Cancer

Spain, Netherlands, Belgium, Egypt, South Africa, Germany, Switzerland, France, Poland, Italy, Czech Republic, Greece
European Inter-group Cooperation on Childhood and...

Unknown

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Lymphoma

France, United Kingdom, Germany, Italy, Belgium, Switzerland, Austria, Czech Republic, Ireland, Netherlands, Poland, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
Novartis Pharmaceuticals

Completed

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Leukaemia

Belgium, Austria, Czechia, France, Germany, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Ireland, Italy, Slovakia, Bulgaria, Singapore, Ukraine, Poland
GlaxoSmithKline

Completed

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome (SCOT)

Lung Cancer, Small Cell

Spain, France, Netherlands, Korea, Republic of, Greece, Slovenia, Italy, Czech Republic, Germany, Austria, Hungary, Poland, Estonia, Lithuania
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
Genentech, Inc.

Completed

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Non-Squamous Non-Small Cell Lung Cancer

Australia, United States, Hungary, France, Germany, Czech Republic, Poland
Astellas Pharma Inc

Completed

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Ovarian Cancer | Solid Tumors

United States, United Kingdom, Australia, Canada, Switzerland, Czechia, Italy, Poland, Romania, Russian Federation
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Small Cell Lung Cancer

Belgium, Denmark, Italy, United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Romania, Spain, United Kingdom
AbbVie

Completed

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Australia, Belgium, Canada, Czechia, France, Hungary, Korea, Republic of, Netherlands, Romania, Russian Federation, Spain
Hoffmann-La Roche

Active, not recruiting

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)

Diffuse Large B-Cell Lymphoma

United States, Canada, France, Spain, Belgium, Korea, Republic of, United Kingdom, Australia, Austria, Czechia, Taiwan, China, Brazil, Japan, Germany, Russian Federation, New Zealand, Hong Kong, Poland, Switzerland, Italy, Turkey, U...
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Australia, Brazil, Spain, Italy, Canada, Germany, Chile, Mexico, France, Argentina, Croatia, Russian Federation, Slovakia, Turkey, Poland, Czechia, New Zealand, Portugal, Greece
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)

Multiple Myeloma

Korea, Republic of, United States, Denmark, Italy, Spain, France, Japan, Israel, United Kingdom, Poland, Australia, Czechia, Canada
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Italy, Poland, Spain, Czechia, Canada, France
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
Boehringer Ingelheim

Completed

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Russian Federation, South Africa, Spain, Sweden, Switzerland
Daiichi Sankyo, Inc.
Parexel

Terminated

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)

Lung Cancer | Non-small Cell Lung Cancer

United States, Italy, Poland, United Kingdom, Belgium, Spain, Canada, Germany, Czechia, Hungary
Celgene

Terminated

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (RENEW)

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, Germany, France, Czechia, Israel, Italy, Poland, Portugal, Puerto Rico, Russian Federation

Clinical Trials on Circulating Tumor Cells in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations